Moderna Inc (MRNA-Q) Analyst Research & Price Targets - The Globe and Mail

Earnings Estimates

	Current Qtr06/2026	Next Qtr09/2026	Fiscal Yr12/2026	Fiscal Yr12/2027
Average Estimate	$-2.00	$-1.10	$-6.51	$-4.39
Number of Estimates	9	9	10	11
High Estimate	$-1.32	$-0.55	$-5.30	$-0.08
Low Estimate	$-2.35	$-1.78	$-7.26	$-5.76
Prior Year	$-2.13	$-0.51	$-7.26	$-6.51
Growth Rate Est. (year over year)	+6.10%	-115.69%	+10.33%	+32.57%

Earnings History - Surprises*

	Qtr Ending03/2026	Qtr Ending12/2025	Qtr Ending09/2025	Qtr Ending06/2025
Reported	$-1.18	$-2.11	$-0.51	$-2.13
Estimate	$-3.02	$-2.60	$-2.15	$-2.99
Difference	+1.84	+0.49	+1.64	+0.86
Surprise	+60.93%	+18.85%	+76.28%	+28.76%

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

2.96

3 Mths Ago24

2.96

2 Mths Ago23

2.88

1 Mth Ago24

2.88

Current24

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	24	23	24	24
	2	2	2	2
Holds	19	18	18	18
	1 2	1 2	1 3	1 3

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

Barlow’s Research Roundup: These stocks are the big winners from Canada’s new nuclear energy plan

Gildan stock is down, and looking good

Why this money manager is buying Agnico Eagle, Nutrien and trimming Alphabet

number cruncher

Top U.S. stocks ranked by Trading Central’s quantitative model

Wednesday’s analyst upgrades and downgrades

number cruncher

Seven Canadian small-cap stocks with cheap valuations

Bullish on Freeport-McMoRan Inc.

Gildan shares sink 19 per cent on short seller report alleging inflated sales